TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05115422

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 'Coping with Brain Fog' program
Description: The proposed intervention is an 8-week 'Coping with Brain Fog' program for cancer survivors, adapted for AYAs with cancer, with one 90-minute group session per week. The intended group size for the program is 8-12 participants. The program was developed to be delivered in person, however for the purposes of this study it will be conducted in a virtual setting. The overall goals of the program are to educate participants about cancer-related brain fog and enhance their cognitive function and wellbeing. To accomplish this, the program is segmented into three main components: memory skills, task management, and psychological wellbeing. For each component, participants are systematically introduced to evidence-based strategies to cumulatively build a repertoire of cognitive tools designed to reduce the impact of cancer-related brain fog. The program uses a manual and participant materials that are copyrighted by Maximum Capacity Inc.
Study: NCT05678244

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: IV acetaminophen will be added to standard of care opioid based pain regimes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In control group placebo will be added to standard of care opioid based pain regimes.
Study: NCT05753891

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suture Tape Reconstruction
Description: This intervention will utilize a suture tape to suspend the 1st and 2nd metacarpal post trapeziectomy compared to the standard procedure of a trapeziectomy followed by ligament reconstruction and tendon interposition.
Study: NCT06179017

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group:Intervention Group
Description: Intervention Group:Interventionist choose the optimal endovascular treatment (EVT) strategy and device based on the patient's condition and local guidelines. The patient will receive the best medical treatment according to the local guidelines.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group:best medical treatment
Description: Best medical treatment:Patients will receive the best medical treatment according to local guidelines, including antiplatelet agents, anticoagulants, thrombolysis, etc., but not any EVT. In the control arm, rescue EVT is allowed in patients with disease progression leading to an increase in NIHSS≥4 and excluding the impact of non-stroke factors, and the onset-to-treatment time is within 24 hours.
Study: NCT05466968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suxiao Jiuxin Pills
Description: Suxiao Jiuxin Pills consists Rhizoma Ligustici (Chuan xiong) and Borneolum (Bing pian).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: The placebo of Suxiao Jiuxin Pills
Description: The placebo of Suxiao Jiuxin Pills is similar to Suxiao Jiuxin Pills in appearance, smell, and taste.
Study: NCT04980755

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Body Reprogramming
Description: An educational intervention originally designed for patients with fibromyalgia.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Body Reprogramming
Description: An educational intervention originally designed for patients with fibromyalgia.
Study: NCT04906707

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EaseVRx
Description: EaseVRx is a commercially available pain management program. It is a multi-modal, skills-based, 8-week, VR, mind-body approach to daily management of chronic pain that is designed for home use to be worn over the eyes. The program contains five types of modules that are as follows: Interoception, Education, 360-degree relaxation videos, Games, and Dynamic breathing. All program content is mapped to a therapeutically designed curriculum with weekly themes. The following core themes are infused into the curriculum: Acceptance, Attention shifting, Awareness, Rehabilitation, Self-compassion, Healthy Movement, Deep relaxation, Visualization, Knowledge of pain, Distraction, and Immersive enjoyment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Audio-only version of EaseVRx
Description: Participants in the control group will be asked to use the audio-only version of EaseVRx, which excludes references to visual content, to complete 7 sessions weekly. They will receive an electronic link to the recordings on SoundCloud (a music streaming platform) where they can choose to stream or download the audio recordings on their smartphone, laptop, or desktop computer.
Study: NCT05814900

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Two photon microscopy imaging
Description: Excised tissues will be imaged with two photon microscopy
Study: NCT06158659

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Feihe Investigational Formula
Description: Participants in this arm will receive stage 1 and stage 2 Feihe investigational formulas. At the first (up to) 6 months, they will be fed with stage1 formula, and then switch to stage 2 formula until 12 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control Formula
Description: Participants in this arm will receive stage 1 and stage 2 Control formulas. At the first (up to) 6 months, they will be fed with stage1 formula, and then switch to stage 2 formula until 12 months.

Intervention type: OTHER
Group type: OTHER
Intervention: Breastfeeding
Description: Exclusively breastfed for the first 4 months and continue with supplement food without any marketed infant formula.
Study: NCT05501015

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ice chips
Description: Consuming small amounts of ice chips with supervision
Study: NCT04827966

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinpro® 5% sodium fluoride plus tri calcium phosphate varnish
Description: Clinpro® is 5% sodium fluoride varnish and is indicated to be used for hypersensitive as well as for demineralized teeth. It flows smoothly on moist teeth and binds firmly to their surfaces. 1ml of Clinpro® contain 50 mg of sodium fluoride

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tooth Mousse® - Casein phosphopeptide-Amorphous calcium phosphate (CPP - ACP)s
Description: Tooth Mousse® contains Casein phosphopeptide-Amorphous calcium phosphate (CPP - ACP) is product from the milk casein. This delivers the necessary Calcium and Phosphate ions to the tooth, which will reduce the risk of caries and white spot by enhancing tooth remineralization.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MI Paste® -Casein phosphopeptide-Amorphous calcium phosphate fluoride (CPP-ACPF)
Description: MI Paste® which is Casein phosphopeptide-Amorphous calcium phosphate fluoride (CPP-ACPF) additional contains fluoride in addition to CPP-ACP. The level of fluoride is 900ppm which approximates that in adult strength toothpastes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Zap® 1.23% APF gel - Acidulated phosphate fluoride
Description: 1.23% APF (Acidulated phosphate fluoride) gel is routinely used professional based fluoride for patients with high caries risk.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Listerine fluoride mouthrinse
Description: Listerine® Sodium fluoride (0.2%) mouth rinses are effective in reducing caries and inhibit carbohydrate utilization of oral microorganisms by blocking enzymes involved in the bacterial glycolytic pathway studies have shown sodium fluoride mouth rinse to be effective in reducing S. mutans counts
Study: NCT06181305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estradiol valerate and letrozole
Description: hormone replacement therapy by estradiol valerate plus letrozole incorporation .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: letrozole 2,5 mg tablet
Description: mild ovarian stimulation
Study: NCT05400733

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Total Amino Acids
Description: Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Threonine, Tryptophan, Valine, Alanine, Arginine, Aspartate, Cystine, Glutamine, Glutamate, Glycine, Proline, Serine, Tyrosine. All supplements are commercially available.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Total Amino Acids
Description: Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Threonine, Tryptophan, Valine, Alanine, Arginine, Aspartate, Cystine, Glutamine, Glutamate, Glycine, Proline, Serine, Tyrosine. All supplements are commercially available.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Essential Amino Acids
Description: Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Threonine, Tryptophan, Valine. All supplements are commercially available.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Essential Amino Acids
Description: Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Threonine, Tryptophan, Valine. All supplements are commercially available.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Essential Amino Acids + Hydroxy-methylbutyric acid (HMB)
Description: Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Threonine, Tryptophan, Valine, HMB. All supplements are commercially available.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Essential Amino Acids + Hydroxy-methylbutyric acid (HMB)
Description: Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Threonine, Tryptophan, Valine, HMB. All supplements are commercially available.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Essential Amino Acids + Leucine
Description: Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Threonine, Tryptophan, Valine, Extra leucine. All supplements are commercially available.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Essential Amino Acids + Leucine
Description: Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Threonine, Tryptophan, Valine, Extra leucine. All supplements are commercially available.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Essential Amino Acids High
Description: Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Threonine, Tryptophan, Valine. All supplements are commercially available.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Essential Amino Acids High
Description: Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Threonine, Tryptophan, Valine. All supplements are commercially available.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo Water
Description: Water

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo Water
Description: Water
Study: NCT05668143

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: The Patient Information Form and the State Anxiety Scale will be administered to the patients just before the surgery. The researcher will measure the patient's respiratory, blood pressure, pulse and oxygen saturation values on the monitor just before the start of the operation and every 15 minutes after the operation, and the vital signs will be recorded in the follow-up form. Virtual reality glasses will be put on the patient immediately after anesthesia is given to the patient by the anesthesiologist. Glasses will be worn during the total knee replacement surgery. Total knee replacement surgery takes an average of 60 minutes. During the surgery, patients will be shown nature and landscape images with virtual reality glasses. Virtual reality glasses will be removed immediately after the operation and the State Anxiety Scale and vital signs follow-up form will be applied before the patient is sent to the service from the operating room.
Study: NCT03825835

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 30% oxygen group
Description: Infants in the 30% oxygen group will remain in 30% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is \<85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.~Intervention: Infants randomized to the 30% oxygen group will receive 30% oxygen at birth for the first 5 minutes. At 5 minutes oxygen can be adjusted as needed.
Study: NCT04930328

Intervention type: DRUG
Intervention: Oxbryta® (voxelotor) 500-mg Tablets
Description: Patients will have received treatment with Oxbryta as prescribed by their physician at the approved dose per local prescribing information, as part of their usual care.
Study: NCT03825835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 60% oxygen group
Description: Infants in the 60% oxygen group will remain in 60% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is \<85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.~Intervention: Infants randomized to the 60% oxygen group will receive 60% oxygen at birth for the first 5 minutes. At 5 minutes oxygen can be adjusted as needed.
Study: NCT05144503

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpherePVI™ Catheter
Description: SpherePVI™ Catheter with the Affera Mapping and Ablation System
Study: NCT05798741

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hardware removal
Description: The surgery of hardware removal after an ORIF of an ankle fracture
Study: NCT04830605

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based treatment
Description: The intervention is an internet-based psychotherapy treatment with eight modules based on acceptance and commitment therapy and with written therapist contact through eight weeks.
Study: NCT05666687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIJ821
Description: MIJ821 will be administered as an i.v. infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIJ821
Description: MIJ821 will be administered as an i.v. infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIJ821
Description: MIJ821 will be administered as an i.v. infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIJ821
Description: MIJ821 will be administered as an i.v. infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIJ821
Description: MIJ821 will be administered as an i.v. infusion
Study: NCT06207370

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tafenoquine
Description: Oral Tafenoquine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05904860

Intervention type: OTHER
Group type: OTHER
Intervention: Backward Gait Training
Description: Backward gait training will be provided within parallel bars, a mirror, and on a firm surface. The harness belt will be around the patient's torso to avoid sudden falls.

Intervention type: OTHER
Group type: OTHER
Intervention: Forward Gait Training
Description: Forward gait training will be provided within parallel bars, a mirror, and on a firm surface. The harness belt will be around the patient's torso to avoid sudden falls.
Study: NCT05072522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKLB1028
Description: SKLB1028 capsules, oral, once daily in continuous 28-day cycles
Study: NCT06406075

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lab demo 1.0
Description: During the intervention, transcutaneous spectral data are collected continuously with the Lab demo. Up to 20 whole blood glucose reference values are also collected, as well as interstitial fluid glucose values using a continuous glucose monitoring device. Some participants will attend multiple measurement sessions.
Study: NCT05844761

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Triggered imaging on TrueBeam with margin reduction
Description: At interim analysis the Planning target volume (PTV) will be reduced based on the accuracy of the TrueBeam triggered imaging motion management technique.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Synchrony MLC tracking on fiducials with margin reduction
Description: At interim analysis the Planning target volume (PTV) will be reduced based on the accuracy of the Radixact Synchrony motion management technique.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Synchrony MLC tracking and lung adaptive model with margin reduction
Description: At interim analysis the Planning target volume (PTV) will be reduced based on the accuracy of the Radixact Synchrony motion management technique for lung cancer.
Study: NCT05424445

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Women presenting at the study site with an indication for IOL will receive written and oral information about the study. They will have the opportunity to ask questions. If the woman agrees to participate and is deemed eligible, she will sign informed consent. The Swedish national guidelines regarding the method of IOL will be followed. Women will have an abdominal palpation to exclude malpresentation, a CTG, and a digital cervical exam to establish bishop score (BS) prior to inclusion (as per clinical practice). Randomization will be performed by the attending physician, midwife or study coordinator. Randomization will be by opening numbered opaque sealed envelopes in sequential order containing the randomization code. There are no restrictions for use of other medications. All concomitant medication will be recorded in the CRF.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Women presenting at the study site with an indication for IOL will receive written and oral information about the study. They will have the opportunity to ask questions. If the woman agrees to participate and is deemed eligible, she will sign informed consent. The Swedish national guidelines regarding the method of IOL will be followed. Women will have an abdominal palpation to exclude malpresentation, a CTG, and a digital cervical exam to establish bishop score (BS) prior to inclusion (as per clinical practice). Randomization will be performed by the attending physician, midwife or study coordinator. Randomization will be by opening numbered opaque sealed envelopes in sequential order containing the randomization code. There are no restrictions for use of other medications. All concomitant medication will be recorded in the CRF.
Study: NCT06488794

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: colistimethate sodium
Description: 30 000 IU/kg of colistimethate sodium (equivalent to 0.96 mg/kg of colistin base) ,maximum 750000 IU, will be nebulized daily, divided into two doses for 3 days for eligible ventilated children starting from day 3 of mechanical ventilation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline
Description: Nebulization of 3 ml of 0.9% saline twice a day for 3 days from day 3 of invasive mechanical ventilation for eligibile ventilated children
Study: NCT05770102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Adult participants will receive 1200 mg of atezolizumab intravenously every 21 days.~Paediatric participants will receive atezolizumab at a dose of 15 mg/kg (maximum 1200 mg) every 21 days.~Participants may continue on treatment until disease progression, unacceptable toxicity or withdrawal of consent.
Study: NCT06461715

Intervention type: OTHER
Intervention: Machine learning with artificial intelligence software program
Description: This is a retrospective observational study using cardiac MRI, cardiac CT and x-ray fluoroscopy images to develop a 3D hybrid guidance system with the use of deep learning methods.
Study: NCT05965635

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ixodus scapularis nymphs
Description: Tick challenge
Study: NCT04916743

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intradialytic exercise group
Description: Participants will do concurrent exercise (a combination of aerobic exercise and resistance training) for 30-60 minutes during the second hour of their routine hemodialysis sessions. To determine the intensity of the prescribed exercise, maximum heart rate is used for aerobic workout and 5 Repetitions Maximum (5RM) for resistance protocols. Exercises will be performed at a moderate exercise intensity (12-14 on the Borg RPE Scale). All protocols are tailor-made based on each individual's needs and physical abilities.
Study: NCT05069142

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: Pre- and post-operative exercise and education.
Study: NCT06519643

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: career planning application
Description: Arm 1 \[Experimental group\]: The experimental group will be assigned to participate in a career planning application named Building Your Successful Nursing Career App for six months. They will receive the full career planning mobile application intervention along with two online career mentoring sessions.~Arm 2 \[Control group\]: The control group will also be assigned to participate in a career planning application named Building Your Successful Nursing Career App for six months. However, the control group will only receive a sham treatment. They will only access a few interfaces of the app.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: career planning application
Description: Arm 1 \[Experimental group\]: The experimental group will be assigned to participate in a career planning application named Building Your Successful Nursing Career App for six months. They will receive the full career planning mobile application intervention along with two online career mentoring sessions.~Arm 2 \[Control group\]: The control group will also be assigned to participate in a career planning application named Building Your Successful Nursing Career App for six months. However, the control group will only receive a sham treatment. They will only access a few interfaces of the app.
Study: NCT05785013

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc
Description: Zinc Supplementation
Study: NCT06307691

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional drilling
Description: Atraumatic extraction, followed by sequential drilling using conventional drills

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Osseodensification drilling
Description: Atraumatic extraction, followed by osteotomy prepared using densah bur (sequential drilling)